Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

340.42 +0.74 (+0.22%)
Streaming Delayed Price Updated: 10:47 AM EST, Feb 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 382,794
Open 338.56
Bid (Size) 340.23 (1)
Ask (Size) 340.53 (2)
Prev. Close 339.68
Today's Range 337.82 - 342.24
52wk Range 231.87 - 384.44
Shares Outstanding N/A
Dividend Yield 1.00%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Is Eli Lilly Stock a Buy Now?
There is a lot to like about this drugmaker, but is it enough? 
Via The Motley Fool
Active Pharmaceutical Ingredients Market May Set Epic Growth Story : Pfizer, Novartis, Sanofi
Stay up-to-date with Active Pharmaceutical Ingredients Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Topics Death
Exposures Death

Performance

YTD
-6.73%
-6.73%
1 Month
-2.69%
-2.69%
3 Month
-7.16%
-7.16%
6 Month
+12.34%
+12.34%
1 Year
+39.77%
+39.77%

More News

Read More
Is Biotech Immunocore About To Make A 25% Price Move?
Via MarketBeat
Topics ETFs
7 A-Rated Stocks to Buy for February 2023
Via InvestorPlace
Analyst Ratings for Eli Lilly
Via Benzinga
Eli Lilly (LLY) Q4 2022 Earnings Call Transcript
Via The Motley Fool
Why Eli Lilly Stock Is Under Pressure Today
Via The Motley Fool
Eli Lilly Sinks On Mixed Earnings Report, But Boosts 2023 Earnings Outlook
Via Investor's Business Daily
1 Company Bucks the Office REIT Trend With Higher Rents and Earnings
Via The Motley Fool
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
Via Investor's Business Daily
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Seasoned Veteran as New Chief Business Officer
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Eli Lilly Q4 Earnings Surpass Estimates
Via Talk Markets
Eli Lilly Posts Weaker Q4 Sales On Slower Demand For Its COVID-19 Treatment, Overshadowing Annual Guidance
Via Benzinga
Looking for a Reliable Dividend Payer? Consider Buying This Blue-Chip Stock
Via The Motley Fool
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
Via Benzinga
Preview: Eli Lilly's Earnings
Via Benzinga
Darryle D. Schoepp, Ph.D., Former Merck and Eli Lilly Executive, Joins Scientific Advisory Board of Akelos Inc., Biotechnology Company Developing Opioid Alternatives
Via Newswire.com
Topics Intellectual Property
Exposures Intellectual Property
Why the FDA's Rejection of Eli Lilly's Alzheimer's Drug Is Actually Great News for the Stock
Via The Motley Fool
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
Via Benzinga
7 Healthcare Stocks That Will Be Big Winners in 2023
Via InvestorPlace
Down 14.5%, Is Pfizer Stock a Screaming Buy?
Via The Motley Fool
FDA Gives Conditional Approval For Eli Lilly's Drug For Rare Blood Cancer
Via Benzinga
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Via MarketBeat
Exposures Product Safety
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
Via Benzinga
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.